Hemorrhagic Fever Disease in STAT-1 Knockout Mice Infected with Lujo Virus

Lujo virus (LUJV) is an arenavirus that causes Lujo Hemorrhagic Fever (LHF), a viral hemorrhagic fever that emerged in a 2007 outbreak in Zambia and South Africa with an 80% case fatality rate and evidence of human-to-human nosocomial transmission. There are no approved medical countermeasures for LHF, although several screens have identified lead antiviral compounds. The lack of accessible animal models limits the development of lead compounds and characterization of broadly protective anti-arenavirus compounds such as ribavirin for the treatment of LHF. Here, we present preliminary data characterizing the partially lethal disease caused by LUVJ in STAT-1 deficient mice. Several key hematological, clinical chemistry, and histologic findings common to LHF disease are recapitulated in this model. This work suggests that further characterization of LUJV infection in STAT-1 deficient mice may allow development of a model that would be instrumental in the development of medical countermeasures for LHF.

Authors

Institutions

Publication Details

Journal
Pathogens
Published
2026-04-07
DOI
https://doi.org/10.3390/pathogens15040394
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hemorrhagic Fever Disease in STAT-1 Knockout Mice Infected with Lujo Virus

Sharon Jan, Dylan M. Johnson, Jason E. Comer, Robert W. Cross et al.
Pathogens
Viral Infections and Outbreaks Research
article

Hemorrhagic Fever Disease in STAT-1 Knockout Mice Infected with Lujo Virus

Sharon Jan, Dylan M. Johnson, Jason E. Comer, Robert W. Cross, Ethan D. Dunn, Thomas W. Geisbert
article en

Abstract

Lujo virus (LUJV) is an arenavirus that causes Lujo Hemorrhagic Fever (LHF), a viral hemorrhagic fever that emerged in a 2007 outbreak in Zambia and South Africa with an 80% case fatality rate and evidence of human-to-human nosocomial transmission. There are no approved medical countermeasures for LHF, although several screens have identified lead antiviral compounds. The lack of accessible animal models limits the development of lead compounds and characterization of broadly protective anti-arenavirus compounds such as ribavirin for the treatment of LHF. Here, we present preliminary data characterizing the partially lethal disease caused by LUVJ in STAT-1 deficient mice. Several key hematological, clinical chemistry, and histologic findings common to LHF disease are recapitulated in this model. This work suggests that further characterization of LUJV infection in STAT-1 deficient mice may allow development of a model that would be instrumental in the development of medical countermeasures for LHF.

PathogensVol. 15(4)
Texas Biomedical Research Institute (US), Sandia National Laboratories California (US), The University of Texas Medical Branch at Galveston (US)
U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
Openalex Percentile: Top 27%
Viral Infections and Outbreaks Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Hemorrhagic Fever Disease in STAT-1 Knockout Mice Infected with Lujo Virus — Sharon Jan, Dylan M. Johnson, et al. · Pathogens (2026) | TGRS Research Map | TGRS